Pfizer’s mRNA Flu Vaccine Demonstrates 34.5% Superiority Over Traditional Shots in Landmark Global Trial
Pfizer's mRNA influenza vaccine outperforms traditional shots by 34.5% in a Phase…
Pfizer’s mRNA Flu Vaccine Achieves 34.5% Higher Effectiveness in Landmark Phase 3 Trial Against Traditional Shots
Pfizer's mRNA flu vaccine outperforms traditional shots by 34.5% in a major…
Pfizer mRNA Flu Vaccine Outperforms Traditional Shots by 34.5% in Pivotal Phase 3 Trial
Pfizer's mRNA influenza vaccine showed 34.5% better efficacy than traditional flu shots…
NIH Terminates Funding for 383 Clinical Trials, Jeopardizing 74,000 Patients and mRNA Vaccine Research Amid Budget Cuts
NIH halts 383 clinical trials due to budget cuts, impacting 74,000 patients…
